New Zealand - English - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - cefalexin monohydrate 525.8mg equivalent to 500 mg cefalexin anhydrous. - capsule - 500 mg - active: cefalexin monohydrate 525.8mg equivalent to 500 mg cefalexin anhydrous. excipient: hard gelatin capsules size "0" tekprint sw-9008 black ink magnesium stearate microcrystalline cellulose

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - cefalexin monohydrate 525.8mg equivalent to cephalexin 500 mg;   - capsule - 500 mg - active: cefalexin monohydrate 525.8mg equivalent to cephalexin 500 mg   excipient: gelatin   magnesium stearate microcrystalline cellulose titanium dioxide   water  

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - cefalexin monohydrate 27.602 mg/ml equivalent to cephalexin 25 mg/ml (+5% stability overage);   - granules for oral suspension - 125 mg/5ml - active: cefalexin monohydrate 27.602 mg/ml equivalent to cephalexin 25 mg/ml (+5% stability overage)   excipient: apple flavour 648601 citric acid guar gum iron oxide yellow raspberry flavour 501183 tp0551 saccharin sodium simeticone sodium benzoate strawberry flavour 052303 bp0551 sucrose tutti frutti flavour 051880 ap0551 - cefalexin is indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: · bacterial sinusitis caused by streptococci, streptococcus pneumoniae, and staphylococcus aureus (methicillin -sensitive only); ·respiratory tract infections caused by s. pneumoniae and streptococcus pyogenes (penicillin is the usual medicine of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever - cefalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefalexin in the subsequent prevention of either rheumatic fever or bacterial endocarditis are not available at present); · otitis media due to s. pneumoniae, haemophilus influenzae, staphylococci, streptococci, and moraxella catarrhalis; · skin and skin-structure infections caused by staphylococci and/or streptococci; · bone infections caused by staphylococci and/or proteus mirabilis; · genitourinary tract infections, including acute prostatitis, caused by eschericia coli, p. mirabilis, and klebsiella pneumoniae; · dental infections caused by staphylococci and/or streptococci. note - culture and susceptibility tests should be initiated prior to and during therapy. renal function studies should be performed when indicated.

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - cefalexin monohydrate 55.206 mg/ml equivalent to cephalexin 50 mg/ml (+5% stability overage);   - granules for oral suspension - 250 mg/5ml - active: cefalexin monohydrate 55.206 mg/ml equivalent to cephalexin 50 mg/ml (+5% stability overage)   excipient: apple flavour 648601 citric acid guar gum iron oxide yellow raspberry flavour 501183 tp0551 saccharin sodium simeticone sodium benzoate strawberry flavour 052303 bp0551 sucrose tutti frutti flavour 051880 ap0551 - cefalexin is indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: · bacterial sinusitis caused by streptococci, streptococcus pneumoniae, and staphylococcus aureus (methicillin -sensitive only); ·respiratory tract infections caused by s. pneumoniae and streptococcus pyogenes (penicillin is the usual medicine of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever - cefalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefalexin in the subsequent prevention of either rheumatic fever or bacterial endocarditis are not available at present); · otitis media due to s. pneumoniae, haemophilus influenzae, staphylococci, streptococci, and moraxella catarrhalis; · skin and skin-structure infections caused by staphylococci and/or streptococci; · bone infections caused by staphylococci and/or proteus mirabilis; · genitourinary tract infections, including acute prostatitis, caused by eschericia coli, p. mirabilis, and klebsiella pneumoniae; · dental infections caused by staphylococci and/or streptococci. note - culture and susceptibility tests should be initiated prior to and during therapy. renal function studies should be performed when indicated.

New Zealand - English - Medsafe (Medicines Safety Authority)

max health limited - cefalexin monohydrate 26.295 mg/ml equivalent to cefalexin 25mg/ml;   - granules for oral suspension - 125 mg/5ml - active: cefalexin monohydrate 26.295 mg/ml equivalent to cefalexin 25mg/ml   excipient: allura red ac dimeticone imitation guarana flavour 051880 tp0551 methylcellulose pregelatinised maize starch sodium laurilsulfate sucrose xanthan gum - cefalexin is indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: - bacterial sinusitis caused by streptococci, s. pneumoniae, and staphylococcus aureus (methicillin -sensitive only); - respiratory tract infections caused by s. pneumoniae and s. pyogenes (penicillin is the usual medicine of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever - cefalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefalexin in the subsequent prevention of either rheumatic fever or bacterial endocarditis are not available at present); - otitis media due to s. pneumoniae, h. influenzae, staphylococci, streptococci, and m. catarrhalis; - skin and skin-structure infections caused by staphylococci and/or streptococci; - bone infections caused by staphylococci and/or p. mirabilis; - genitourinary tract infections, including acute prostatitis, caused by e. coli, p. mirabilis, and klebsiella pneumoniae; - dental infections caused by staphylococci and/or streptococci. note - culture and susceptibility tests should be initiated prior to and during therapy. renal function studies should be performed when indicated.

New Zealand - English - Medsafe (Medicines Safety Authority)

max health limited - cefalexin monohydrate 52.591 mg/ml equivalent to cefalexin 50mg/ml;   - granules for oral suspension - 250 mg/5ml - active: cefalexin monohydrate 52.591 mg/ml equivalent to cefalexin 50mg/ml   excipient: allura red ac dimeticone imitation guarana flavour 051880 tp0551 methylcellulose pregelatinised maize starch sodium laurilsulfate sucrose xanthan gum - cefalexin is indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: - bacterial sinusitis caused by streptococci, s. pneumoniae, and staphylococcus aureus (methicillin -sensitive only); - respiratory tract infections caused by s. pneumoniae and s. pyogenes (penicillin is the usual medicine of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever - cefalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefalexin in the subsequent prevention of either rheumatic fever or bacterial endocarditis are not available at present); - otitis media due to s. pneumoniae, h. influenzae, staphylococci, streptococci, and m. catarrhalis; - skin and skin-structure infections caused by staphylococci and/or streptococci; - bone infections caused by staphylococci and/or p. mirabilis; - genitourinary tract infections, including acute prostatitis, caused by e. coli, p. mirabilis, and klebsiella pneumoniae; - dental infections caused by staphylococci and/or streptococci. note - culture and susceptibility tests should be initiated prior to and during therapy. renal function studies should be performed when indicated.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - cefalexin monohydrate, quantity: 262.94 mg (equivalent: cefalexin, qty 250 mg) - capsule - excipient ingredients: colloidal anhydrous silica; magnesium stearate; lactose; titanium dioxide; brilliant blue fcf; purified water; quinoline yellow; allura red ac; gelatin; sodium lauryl sulfate - cephalexin is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms:,- respiratory tract infections caused by s. pneumoniae and group a beta-haemolytic streptococci (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present.),- bacterial sinusitis caused by streptococci, s. pneumoniae and s. aureus (methicillin-sensitive only),- otitis media due to s. pneumoniae, staphylococci,- skin and soft-tissue infections caused by staphylococci and/or streptococci,- genitourinary tract infections, including acute prostatitis caused by e. coli, p. mirabilis, and klebsiella sp.,the effectiveness of cephalexin in the treatment of bacterial infections of the brain and spinal column has not been established and cephalexin is not indicated in these conditions.,note: appropriate culture and susceptibility tests should be initiated prior to and during therapy to determine susceptibility of the causative organism to cephalexin. renal function studies should be performed when indicated.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - cefalexin monohydrate, quantity: 525.87 mg (equivalent: cefalexin, qty 500 mg) - capsule - excipient ingredients: magnesium stearate; colloidal anhydrous silica; lactose; titanium dioxide; brilliant blue fcf; quinoline yellow; purified water; gelatin; sodium lauryl sulfate - cephalexin is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms:,- respiratory tract infections caused by s. pneumoniae and group a beta-haemolytic streptococci (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present.),- bacterial sinusitis caused by streptococci, s. pneumoniae and s. aureus (methicillin-sensitive only),- otitis media due to s. pneumoniae, staphylococci,- skin and soft-tissue infections caused by staphylococci and/or streptococci,- genitourinary tract infections, including acute prostatitis caused by e. coli, p. mirabilis, and klebsiella sp.,the effectiveness of cephalexin in the treatment of bacterial infections of the brain and spinal column has not been established and cephalexin is not indicated in these conditions.,note: appropriate culture and susceptibility tests should be initiated prior to and during therapy to determine susceptibility of the causative organism to cephalexin. renal function studies should be performed when indicated.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - cefalexin monohydrate, quantity: 262.94 mg (equivalent: cefalexin, qty 250 mg) - capsule - excipient ingredients: lactose; colloidal anhydrous silica; magnesium stearate; titanium dioxide; brilliant blue fcf; purified water; quinoline yellow; allura red ac; gelatin; sodium lauryl sulfate - cephalexin is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms:,- respiratory tract infections caused by s. pneumoniae and group a beta-haemolytic streptococci (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present.),- bacterial sinusitis caused by streptococci, s. pneumoniae and s. aureus (methicillin-sensitive only),- otitis media due to s. pneumoniae, staphylococci,- skin and soft-tissue infections caused by staphylococci and/or streptococci,- genitourinary tract infections, including acute prostatitis caused by e. coli, p. mirabilis, and klebsiella sp.,the effectiveness of cephalexin in the treatment of bacterial infections of the brain and spinal column has not been established and cephalexin is not indicated in these conditions.,note: appropriate culture and susceptibility tests should be initiated prior to and during therapy to determine susceptibility of the causative organism to cephalexin. renal function studies should be performed when indicated.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - cefalexin monohydrate, quantity: 525.87 mg (equivalent: cefalexin, qty 500 mg) - capsule - excipient ingredients: lactose; magnesium stearate; colloidal anhydrous silica; titanium dioxide; brilliant blue fcf; quinoline yellow; purified water; gelatin; sodium lauryl sulfate - cephalexin is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms:,- respiratory tract infections caused by s. pneumoniae and group a beta-haemolytic streptococci (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present.),- bacterial sinusitis caused by streptococci, s. pneumoniae and s. aureus (methicillin-sensitive only),- otitis media due to s. pneumoniae, staphylococci,- skin and soft-tissue infections caused by staphylococci and/or streptococci,- genitourinary tract infections, including acute prostatitis caused by e. coli, p. mirabilis, and klebsiella sp.,the effectiveness of cephalexin in the treatment of bacterial infections of the brain and spinal column has not been established and cephalexin is not indicated in these conditions.,note: appropriate culture and susceptibility tests should be initiated prior to and during therapy to determine susceptibility of the causative organism to cephalexin. renal function studies should be performed when indicated.